Drug Profile

Anti PD 1 sustained release therapeutic - UroGen Pharma

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UroGen Pharma
Class Antineoplastics; Immunotherapies
Mechanism of Action Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Apr 2025 No recent reports of development identified for research development in Glioblastoma in USA
15 Mar 2021 Anti PD 1 sustained release therapeutic - UroGen Pharma is available for licensing as of 15 Mar 2021. https://www.urogen.com/our-pipeline-and-partners/
15 Mar 2021 UroGen Pharma enters into a research agreement with the Johns Hopkins University to study checkpoint inhibitors in glioblastoma multiformein

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com